Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

  title={Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.},
  author={Tamara Isakova and Joachim H. Ix and Stuart M. Sprague and Kalani L. Raphael and Linda F. Fried and Jennifer J. Gassman and Dominic S. C. Raj and Alfred K. Cheung and John W. Kusek and Michael Francis Flessner and Myles Wolf and Geoffrey A. Block},
  journal={Journal of the American Society of Nephrology : JASN},
  volume={26 10},
  • T. IsakovaJ. Ix G. Block
  • Published 12 May 2015
  • Biology, Medicine
  • Journal of the American Society of Nephrology : JASN
Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet available therapies only modestly improve clinical outcomes. Observational studies report independent associations between elevated serum phosphate and fibroblast growth factor 23 (FGF23) levels and risks of ESRD, CVD, and death. Phosphate excess induces arterial calcification, and although elevated FGF23 helps maintain serum phosphate levels in the normal range in CKD, it may contribute mechanistically to… 

Figures and Tables from this paper

Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study

The primary objective of the IMPROVE-CKD study is to determine if the use of lanthanum carbonate reduces the burden of cardiovascular disease in patients with CKD stages 3b and 4 when compared with placebo.

A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).

In patients with stage 3b/4 CKD, treatment with lanthanum over 96 weeks did not affect arterial stiffness or aortic calcification compared with placebo, and the role of intestinal phosphate binders to reduce cardiovascular risk in patients with CKD who have normophosphatemia is not supported.

Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.

Phosphate binders can effectively reduce serum intact FGF23 levels in CKD patients, and iron-based phosphate binders have better effect on reducing serum intactfibroblast growth factor 23 levels than other phosphate Binders.

Should phosphate management be limited to the KDIGO/ KDOQI guidelines?

There has been a lack of high quality evidence demonstrating beneficial effects of phosphate lowering therapy on clinical outcomes, and there is no definitive data as to whether effective phosphate control with phosphate binders will prevent elevations in FGF 23, and whether lowering FGF23 levels will lead to improved patient outcomes.

Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho.

Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony

It is suggested that FGF23 are elevated and may also be a risk factor for cardiovascular disease and mortality in type 2 diabetes patients without CKD, although the magnitude of the association is smaller than in CKD patients.

Total Phosphate Elimination is Negatively Associated With Increased Serum Fibroblast Growth Factor 23 Levels in Patients who Undergo Peritoneal Dialysis

  • S. YamadaK. Tsuruya T. Kitazono
  • Medicine, Biology
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2017
It is indicated that maintaining phosphate elimination can prevent increased sFGF23, thereby preventing cardiovascular events in patients who undergo PD.

The role of calcium and non calcium‐based phosphate binders in chronic kidney disease

In general, it seems prudent to avoid prescribing calcium‐based drugs to patients who are pre‐dialysis, and to use non‐CBBs preferentially in CKD stage 5D, while current draft Kidney Disease Improving Global Outcomes guidelines suggest that CBB dosage be minimized in CKd stages 3 to 5D.

The Urinary Phosphate to Serum Fibroblast Growth Factor 23 Ratio Is a Useful Marker of Atherosclerosis in Early-Stage Chronic Kidney Disease

It is suggested that a decrease in nephron index reflects early-stage renal impairment and is an independent risk factor of macroangiopathy in diabetic patients.



Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease

It is suggested that future population-level and individual-level interventions will need to simultaneously target these molecules to reduce the risk of associated cardiovascular events.

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Prospective and long-term studies are necessary to confirm the effects of sevelamer on serum FGF23 and the benefits of this decrease on outcomes and the positive effects of early prescription of phosphate binders on PTH control.

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

Increased FGF23 is a common manifestation of CKD that develops earlier than increased phosphate or PTH, and may be a sensitive early biomarker of disordered phosphorus metabolism in patients with CKD and normal serum phosphate levels.

Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.

  • T. IsakovaO. Gutiérrez M. Wolf
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2011
Although dietary phosphorus restriction and lanthanum lowered urinary phosphate excretion consistent with a rapid decrease in phosphorus absorption, inducing a reduction in FGF23 levels in CKD patients may require interventions with a longer duration than in healthy volunteers.

Effects of Phosphate Binder Therapy on Vascular Stiffness in Early-Stage Chronic Kidney Disease

Twelve months of LaCO3 had no effect on serum phosphorus and did not alter phosphate homeostasis, PWV, cIMT, VC, or biomarkers of CKD-MBD.

Forging forward with 10 burning questions on FGF23 in kidney disease.

  • M. Wolf
  • Medicine, Biology
    Journal of the American Society of Nephrology : JASN
  • 2010
A proliferation of studies linking phosphorus and now FGF23 excess to adverse renal and cardiovascular outcomes in patients with CKD is setting the stage for novel clinical trials that could ultimately bring FGF 23 testing into the clinic.

Mineral metabolites and CKD progression in African Americans.

In conclusion, abnormalities of mineral metabolism worsen with progressive CKD and associate with higher risk for ESRD among African Americans with hypertensive nephrosclerosis.

Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.

The combination of LC plus counseling for a phosphate-restricted diet decreased FGF23 levels in patients with CKD stages 3-4 and normal serum phosphate levels.

Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease.

FGF23 normalizes serum phosphate and decreases 1, 25-dihydroxyvitamin D levels in early-stage CKD, and suggests a pathological sequence of events for the development of secondary hyperparathyroidism triggered by increased FGF23, followed by a reduction of 1,25-dhydroxy vitamin D and calcium levels, thereby increasing parathyroid hormone secretion.

Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.

  • M. YılmazA. Sonmez C. Zoccali
  • Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2012
In hyperphosphatemic patients with stage 4 CKD, treatment with phosphate lowering induces measurable improvements in flow-mediated vasodilatation, compatible with the hypothesis that FGF-23 may contribute to vascular dysfunction in this population.